Back to Journals » Drug Design, Development and Therapy » Volume 13

Dabigatran must be used carefully: literature review and recommendations for management of adverse events

Authors Lin S, Wang Y, Zhang L, Guan W

Received 29 January 2019

Accepted for publication 16 April 2019

Published 6 May 2019 Volume 2019:13 Pages 1527—1533


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Qiongyu Guo

Shan Lin,* Yan Wang,* Lei Zhang, Wei Guan

Department of Respiratory Medicine, Qinghai University Affiliated Hospital, Xining 810001, People’s Republic of China

*These authors contributed equally to this work

Atrial fibrillation increases the risk of stroke and death. The vitamin-K antagonist warfarin is recommended for patients with atrial fibrillation, but vitamin-K antagonists are cumbersome to use. Therefore, an effective, safe and convenient new anticoagulant is needed. Dabigatran acts by inhibiting free and fibrin-bound thrombin directly. It is an oral anticoagulant that was approved by the US Food and Drug Administration. The oral anticoagulant dabigatran has been used increasingly due to its good tolerance, predictable pharmacokinetics, effective anticoagulant effects, and absence of requirement of coagulation monitoring. However, an increasing prevalence of adverse events has been reported, some of them quite serious. Therefore, we searched and reviewed the literature on dabigatran with regard to adverse events, and proposed solutions to prevent and reduce the chance of adverse events occurring.

Keywords: adverse events, dabigatran, allergic reactions, bleeding, esophageal injury

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]